RE:RE:RE:RE:RE:Back to patent actionInfinity wrote: Pandora, Thanks for sharing the research. I am not sure about the Legal terminology in the event of a dispute arising etc. I understand that the Patent is for a Vaccine for treating cancer??. I believe Theralase applied for a Patent using the cancer cells de-activated by using Rutherin+ TLD 1433...for treatment of Colo - rectal cancers. I did not see any news from theralase if this is being re-vived and possibly used for NMIBC....
Infinity although I have trouble with the legalese I might say that it is a simple form compared to the written dialogue of a medical patent. I could paste the whole patent literature here but I'm not sure anyone would have the interest to go through it -- and it is very long and formatted too tightly to be easy reading. It is rather deep.
The patent dialogue has two major sections, "Claims" and "Description". Reference to TLD1433 shows up in the Description section. It seems all of their compounds or formulas are referenced in the following format such as ##STR00001## or ##STR00022##. The Claims section, which is first, makes reference to items ##000022## through ##STR00056##.
The Description section refers to ##STR00001## through ##STR00021# and has this 'first' reference statement to TLD1433:
"[0075] In certain embodiments of the treatment method, the metal-based coordination complex has the structure of formula (II) below:
##STR00021## and is
sometimes identified herein as TLD1433." i.e. right near the end it references TLD1433.
The Descriptions section ends by giving some examples re rats and humans. The humans examples are:
Example 2 Human (Prophetic)
[0138] Tumor biopsy samples will be used to prepare PDT treated tumor cells vaccines. A single cell suspension of whole tumor mass is prepared by enzymatic digestion with collagenase D or by mechanical disruption. The single cell suspension will be put into suitable media with
2 uM TLD1433 and 10 mg/ml human apo-transferrin. Cells will then be incubated for 4 hours. After 4 hours, the cells will be spun down and washed with PBS. Finally, cells will be suspended in PBS at 10.times.10.sup.6 cells/ml concentration. This suspension will be placed in a sterile 3.5 mm diameter tissue culture dish. Then these cells will be irradiated with 525 nm wavelength green light at 90 J/cm.sup.2. The immunogenic composition comprising a mixture of apoptotic, necrotic and DAMPs will be intramuscularly injected in to same patients. We expect that this PDT treated vaccine will be a strong therapeutic vaccine to induce robust anti-tumor immune response and also antigen spread by identifying new tumor antigens.
Example 4 Dendritic Cell Vaccine in Human Model (Prophetic)
[0145] Leukopheresis monocytes are separated from human cancer patients. They are grown to differentiate into DCs with a cocktail of cytokines. Differentiated DCs are characterized by different DC markers. Upon confirming the expression, those cells are co-incubated with PDT-treated tumor cells from the same patient. Upon co-culture, the DCs will present tumor antigens on HLA molecules. These armed DCs are then transferred back to the same patient as a cancer vaccine. This infusion of DCs could be through various routes at different doses and different time points.
Example 6 Adoptive T Cell Therapy in a Human Model
[0148] Activated DCs are prepared as in Example 4. CD8 T cells are separated from tumor infiltrated T cells, after a tumor is surgically excised. CD8 T cells could also be separated by leukopheresis. The CD8 T cells are grown in the presence of activated DCs along with cocktail of cytokines. Later, activated and expanded CD8 T cells are reintroduced into the same patient to treat cancer.
[0149] While the invention has been described in detail and with reference to specific examples thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.
Anyone wanting to read the whole thing can go to USPTO and hover over "Find it fast" and then in the Patents section click on "Search Assignment" which brings you to Quick Lookup. Under "Lookup By" click on "Select One" and then "Assignee Name" then move over to "Enter name & number" and enter "Theralase Technologies Inc."
A list will come up from which you can select Publication Number 20200222450.
On the page that comes up you will see an item "AppFT" in the top right. Click on that and you get the whole patent write up.
And now you know everything I know. :-))